Goldman Sachs Maintains Buy on HCA Healthcare, Lowers Price Target to $485

Benzinga Newsdesk www.benzinga.com Negative 51.1%

Neg 51.1% Neu 0% Pos 0%

Goldman Sachs analyst Scott Fidel maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $558 to $485.